Facile and efficient one-pot protocol for synthesis of 5-phenyl-1,4- benzodiazepine-2-one derivatives

Synthetic Communications

Volumn 38, Issue 2, 2008, Pages 297-302

  Safaei Ghomi, Javad ^a   Hatami, Alireza ^a  

^a UNIVERSITY OF KASHAN   (Iran)

Author keywords

1,4 benzodiazepine 2 one; 2 aminobenzophenone; One pot synthesis

Indexed keywords

2 AMINOBENZOPHENONE; 5 PHENYL 1,4 BENZODIAZEPINE 2 ONE DERIVATIVE; 5 PHENYL BENZODIAZEPINE 2 ONE 7 CARBOXILIC ACID; 6,7 DICHLORO 5 PHENYL BENZODIAZEPINE 2 ONE; 7 BROMO 5 PHENYL BENZODIAZEPINE 2 ONE; 7,9 DICHLORO 5 PHENYL BEZODIAZEPIN 2 ONE; BENZENE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ONE POT SYNTHESIS;

EID: 38349186408     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397910701750078     Document Type: Article

References (19)

1. (a) Sternbach, L. H. 1,4-Benzodiazepines: Chemistry and some aspects of the structure activity relationship. Angew. Chem. Int. Ed. 1971, 10, 34-40;
2. (b) Walsh, D. A. The synthesis of 2-aminobenzophenones. Synthesis 1980, 9, 677-688.
3. (a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. G.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery - Development of point, selective, orally effective cholecystokinin antagonist. J. Med. Chem. 1988, 31, 2235-2246;
4. (b) Patchett, A. A.; Nargund, R. P. Privileged structures - An update. Annu. Rep. Med. Chem. 2000, 35, 289-298.
5. Sternbach, L. H. Benzodiazepine story. J. Med. Chem. 1979, 22, 1-7.
6. Herrero, S.; Garcýa-López, M. T.; Herranz, R. Expedient one-pot synthesis of novel chiral 2-substituted 5-phenyl-1,4-benzodiazepine scaffolds from amino acid-derived amino nitriles. J. Org. Chem. 2003, 68, 4582-4585.
7. Hanley, D. F.; Pozo, M. Treatment of satus epilepticus with midazolam in the critical care setting. Int. J. Clin. Pract. 2000, 54, 30-35.
8. Hsu, M. C.; Schutt, A. D.; Holly, M.; Slice, L. W.; Sherman, M. I.; Richman, D. D.; Potash, M. J.; Volsky, D. J. Inhibition of HIV replication in acute and chronic infections in vitro by a TAT antagonist. Science 1991, 254, 1799-1802.
9. Ks by (R)-2-(2,4-trifluoromethyl)-N-[2- oxo-5phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl]acetamide. J. Med. Chem. 1997, 40, 3865-3868.
10. (a) James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Marsters, J. C. Benzodiazepine peptidomimetics - Potent inhibitors of ras farnesylation in animal cells. Science 1993, 260, 1937-1942;
11. (b) Liskamp, R. M. J. A new application of modified peptides and peptidomimetics - Potential anticancer agents. Angew. Chem., Int. Ed. Engl. 1994, 33, 305-307.
12. (a) Wyatt, P. G.; Allen, M. J.; Chilcott, J.; Hickin, G.; Miller, N. D.; Woollard, P. M. Structure-activity relationship investigations of a potent and selective benzodiazepine oxytoxin antagonist. Bioorg. Med. Chem. Lett. 2001, 11, 1301-1305;
13. (b) Dziadulewicz, E. K.; Brown, M. C.; Dunstan, A. R.; Lee, W.; Said, N. B.; Garratt, P. J. The design of non-peptide human bradykinin B-12 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg. Med. Chem. Lett. 1999, 9, 463-468;
14. (c) Anzini, M.; Canullo, L.; Braile, C.; Cappelli, A.; Gallelli, A.; Vomero, S.; Menziani, M. C.; Benedetti, P. G. D.; Rizzo, M.; Collina, S.; Azzolina, O.; Sbacchi, M.; Ghelardini, C.; Galeotti, N. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4- benzodiazepines as opioid receptor agonists endowed with antinociceptive and antiamnesic activity. J. Med. Chem. 2003, 46, 3853-3864;
15. 2) antagonists. J. Med. Chem. 2005, 48, 6803-6812.
16. Semple, G.; Ryder, H.; Rooker, D. P.; Batt, A. R.; Kendrick, D. A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishiha, A.; Akuzawa, S.; Miyata, K. (3R)-N-(1-(tert-Butyl-carbonylmethyl)-2, 3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl) -N′-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. J. Med. Chem. 1997, 40, 331-341.
17. Micale, N.; Vairagoundar, R.; Yakovlev, A. G.; Kozikowski, A. P. Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J. Med. Chem. 2004, 47, 6455-6458.
18. Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Reeder, E.; Sach, G.; Saucy, G.; Stempel, A. Quinazolines and 1,4-benzodiazepines, VI: Halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 1962, 27, 3788-3796.
19. Bolli, M. H.; Marfurt, J.; Grisostomi, C.; Boss, C.; Binlcert, C.; Hess, P.; Treiber, E.; Thorin, A.; Morrison, K.; Buchmann, S.; Bur, D.; Ramuz, H.; Clozel, M.; Fischli, W.; Weller, T. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J. Med. Chem. 2004, 47, 2776-2795.